文献速递预防保健、筛查与疫苗妇女保健

人乳头瘤病毒:筛查、检测与预防

Human Papillomavirus: Screening, Testing, and Prevention.
PubMed 文献 · Am Fam Physician · 2021-01-01

人乳头瘤病毒(HPV)是美国最常见的性传播感染,多数感染为一过性且亚临床,但高危黏膜型持续感染可致肛门癌、宫颈癌、口咽癌、阴茎癌、阴道癌和外阴癌。筛查可识别癌前病变并预防癌症,疫苗是主要预防手段,九价疫苗对未感染患者可有效预防高级别宫颈癌前病变。

要点

  • HPV是最常见性传播感染,多数一过性,高危型持续感染可致癌。
  • 筛查可识别癌前病变,为预防癌症提供干预机会。
  • 疫苗是主要预防手段,九价疫苗可预防高级别宫颈癌前病变。

核心结论

  • HPV感染常见且多为暂时性,但高危型持续感染可导致多种癌症,筛查和疫苗接种是关键的预防策略。

研究设计与样本

  • 本文为综述,汇总了HPV感染的临床表现、危险因素、筛查和预防措施的相关证据。

主要发现

  • 已识别200多种HPV型别,感染常累及皮肤和黏膜。
  • 持续感染高危黏膜型(尤其HPV-16和HPV-18)可致肛门癌、宫颈癌、口咽癌、阴茎癌、阴道癌和外阴癌。
  • 多性伴、过早开始性行为、未使用屏障保护、其他性传播感染(包括HIV)、免疫抑制、饮酒和吸烟是持续HPV感染的危险因素。
  • 九价HPV疫苗可有效预防未感染患者发生高级别癌前宫颈病变。

关键数值与推荐

  • 筛查有助于识别癌前病变并允许干预以预防癌症。
  • 疫苗理想接种年龄为11或12岁,无论性别。
  • 一般15岁前接种推荐两剂系列;免疫抑制者需三剂。

临床怎么用

  • 全科医生应识别HPV感染危险因素,建议使用安全套和牙科橡皮障以减少病毒传播。
  • 按推荐年龄(11或12岁)为所有性别患者接种HPV疫苗,15岁前两剂,免疫抑制者三剂。
  • 开展HPV筛查以发现癌前病变并及时干预。

局限性

  • 本文为综述,未报告原始研究的具体样本量、置信区间或P值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

With more than 200 types identified, human papillomavirus (HPV) commonly causes infections of the skin and mucosa. HPV infection is the most common sexually transmitted infection in the United States. Although most HPV infections are transient and subclinical, some lead to clinical manifestations ranging from benign papillomas or warts to intraepithelial lesions. In some patients, persistent infection with high-risk mucosal types, especially HPV-16 and HPV-18, causes anal, cervical, oropharyngeal, penile, vaginal, and vulvar cancers. Most HPV-related cancers are believed to be caused by sexual spread of the virus. A history of multiple sex partners; initiation of sexual activity at an early age; not using barrier protection; other sexually transmitted infections, including HIV; an immunocompromised state; alcohol use; and smoking have been identified as risk factors for persistent HPV infections. Screening for HPV infection is effective in identifying precancerous lesions and allows for interventions that can prevent the development of cancer. Use of condoms and dental dams may decrease spread of the virus. Vaccination is the primary method of prevention. The nonavalent HPV vaccine is effective in preventing the development of high-grade precancerous cervical lesions in noninfected patients. Vaccination is ideally administered at 11 or 12 years of age, irrespective of the patient's sex. In general, a two-dose series is recommended if administered before 15 years of age; however, individuals who are immunocompromised require three doses.

来源:Am Fam Physician,查看原文。版权归原作者所有。

引用

  1. Quinlan JD. Human Papillomavirus: Screening, Testing, and Prevention. Am Fam Physician. 2021. PMID: 34383440

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。